MedPath

Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5
Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.

Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.

Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.

Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.

Associated Conditions
Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
Associated Therapies
-

Transporter Cocktail Mutual Interaction

First Posted Date
2016-08-03
Last Posted Date
2023-11-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02854527
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Transfusion-Associated Circulatory Overload Best Eliminated With Lasix

Early Phase 1
Completed
Conditions
Transfusion-associated Circulatory Overload
Interventions
Drug: Normal Saline
Drug: Furosemide
First Posted Date
2016-06-16
Last Posted Date
2017-06-26
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
80
Registration Number
NCT02802696
Locations
🇨🇦

Canadian Blood Services, Toronto, Ontario, Canada

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

🇨🇦

University Health Network, Toronto, Ontario, Canada

Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients Recovery in the Short Term

Not Applicable
Terminated
Conditions
Oliguria
Critical Illness
Interventions
First Posted Date
2016-06-15
Last Posted Date
2019-06-14
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Target Recruit Count
93
Registration Number
NCT02800135
Locations
🇫🇷

CHU de CLERMONT-FERRAND, Clermont-ferrand, France

🇫🇷

CHU de MONTPELLIER, Montpellier, France

🇫🇷

CHRU de STRASBOURG, Strasbourg, France

and more 1 locations

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

Phase 4
Withdrawn
Conditions
Acute Heart Failure
Interventions
First Posted Date
2016-05-10
Last Posted Date
2018-10-31
Lead Sponsor
Montefiore Medical Center
Registration Number
NCT02767024
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Brain Relaxation With Mannitol and Furosemide

Not Applicable
Completed
Conditions
Brain Tumors
Interventions
First Posted Date
2016-03-18
Last Posted Date
2016-03-18
Lead Sponsor
Istanbul University
Target Recruit Count
47
Registration Number
NCT02712476

Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients

Phase 3
Conditions
Heart Failure
Interventions
Drug: Placebo
Drug: Furosemide
First Posted Date
2016-02-23
Last Posted Date
2016-02-23
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
230
Registration Number
NCT02689180
Locations
🇧🇷

Cardiovascular Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF

Not Applicable
Withdrawn
Conditions
Heart Decompensation
Interventions
First Posted Date
2016-01-08
Last Posted Date
2023-03-21
Lead Sponsor
Chinese University of Hong Kong
Registration Number
NCT02649998
Locations
🇭🇰

Prince of Wales Hospital, Sha Tin, NT, Hong Kong

DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-10-14
Last Posted Date
2023-11-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT02574845
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive

Phase 4
Completed
Conditions
Pulmonary Embolism
Interventions
Drug: Furosemide
Drug: NaCl 9% isotonic
First Posted Date
2015-08-24
Last Posted Date
2020-09-25
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Target Recruit Count
60
Registration Number
NCT02531581
Locations
🇫🇷

CHU de Nice, Nice, France

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

Phase 2
Completed
Conditions
Bronchopulmonary Dysplasia
Interventions
First Posted Date
2015-08-19
Last Posted Date
2021-12-28
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
82
Registration Number
NCT02527798
Locations
🇺🇸

West Virginia University, Morgantown, West Virginia, United States

🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

🇺🇸

MetroHealth Medical Center, Cleveland, Ohio, United States

and more 18 locations
© Copyright 2025. All Rights Reserved by MedPath